|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||55.56 - 56.63|
|52 Week Range||53.63 - 66.80|
|PE Ratio (TTM)||54.54|
|Forward Dividend & Yield||1.92 (3.46%)|
|1y Target Est||N/A|
Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer. Shares of Merck have fallen 10 percent since the drugmaker several weeks ago said it would make survival a main goal of a key lung cancer trial for immunotherapy Keytruda, extending the study by up to a year. In the meantime, Roche Holding AG has shaken up Wall Street expectations for the $15-billion (£11.3 billion) lung cancer market, showing its Tecentriq immunotherapy slows the spread of advanced lung cancer when combined with older treatments.
Combining Roche's Tecentriq immunotherapy with its older drug Avastin for the initial treatment of advanced kidney cancer reduced the risk of the disease worsening or of death in certain patients, the Swiss drugmaker said on Monday. The trial tested the combination against the current standard of care, Pfizer's Sutent, in patients with inoperable, locally advanced or metastatic renal cell carcinoma.
Tecentriq, whose sales pale compared to established immunotherapies from Bristol-Myers Squibb and Merck & Co Inc, is a pillar of Roche's plan to replace revenue from its $20 billion-per-year trio of Avastin, Herceptin and Rituxan whose expiring patents have exposed them to cheaper competition. As a consequence, Roche is seeking to expand indications and patients eligible for treatment with its drug, which analysts see topping $4.6 billion in annual sales by 2023.
Important news for shareholders and potential investors in Merck & Co Inc (NYSE:MRK): The dividend payment of $0.48 per share will be distributed into shareholder on 08 January 2018, andRead More...
Details the 52-week lows of the following companies: General Electric, Merck & Co, Schlumberger, Enterprise Products Partners, Kinder Morgan and Edison International
After lagging rivals in cancer immunotherapies, Swiss drugmaker Roche hopes to leap-frog into the lead in the biggest market, tackling previously untreated lung cancer. "We have a real chance to be at the forefront here," Chief Executive Severin Schwan said on Wednesday.
Merck Chairman and CEO Stefan Oschmann weighs in on the business environment in China and how that has affected the pharmaceutical industry.